Picobirnaviruses (PBVs) have recently been classified into the Picobirnaviridae family. They are small, non-enveloped viruses with bisegmented, double-stranded (ds) RNA genomes. Although they are found in the feces of a broad range of hosts, information regarding their genomes is limited to viruses detected from humans, rabbits, and porcine. Identification of PBVs has been done using PAGE and reverse transcription PCR (RT-PCR). In this study, we present a phylogenetic analysis of PBVs detected in the feces of dogs, snakes, and rats. In addition, we compare these strains to those from human and porcine hosts. To do so, 487 fecal specimens from dogs, snakes and rats were analyzed by PAGE. The positive specimens for PBV were tested by RT-PCR using primers for genogroup I of the PBVs. From the 11 genogroup I PBV samples, at least one from each host was sequenced and submitted for phylogenetic analysis. All of the sequences showed high homology with the human and porcine genogroup I PBV sequences. In this study we report the first detection of PBVs in snakes (8.5%). We also report a phylogenetic analysis that goes beyond humans and pigs to include dogs, rats, and snakes. However, more hosts must be included in the analysis so that we may reach better conclusions regarding the spread of these viruses.

No abstract

Introduction: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared to that of pentavalent antimonial in a pilot study. Methods: We performed a randomized clinical trial with two parallel groups. The tested intervention consisted of miltefosine 1.3-2 mg/kg/day (two capsules) for 28 days or intravenous 20 mg SbV/kg/day of meglumine antimoniate (N-MA) for 30 days. The final endpoint was defined as complete healing of the lesion four years after treatment. We also analyzed an early endpoint at 90 days after treatment. Results: Forty patients were included in this study: each experimental group comprised 20 patients. Applying a multivariate model in an intention-to-treat analysis, we observed that patients treated with miltefosine had a cure probability 2.08 times greater (95% confidence interval [CI] = 1.03-4.18) than those treated with N-MA at 90 days after treatment. At the final endpoint, we observed no differences in cure probability between miltefosine and N-MA (relative risk = 0.66; 95% CI = 0.33-1.32). With respect to adverse reactions, significant differences between groups were related to gastrointestinal effects, which were more frequent in the miltefosine group. Conclusions: Miltefosine may be an interesting alternative for treating ML because of its oral administration and cure rate after long-term follow-up.

Background: Throughout history, wigs have often had a relevant cultural and social importance with correlations to wealth and position of power. Wigs help minimize the psychological consequences of different types of hair loss. They may reduce potential experiences of stigmatization, and improve social confidence and quality of life, besides enhancing self-esteem and social adjustment. In dermatology, wigs may have a positive impact on the global treatment of patients suffering from alopecia as they offer an immediate and efficient cosmetic result. However, the medical literature on wigs is not extensive. Aims: This review aims to discuss synthetic wigs and nonsynthetic custom-made hair systems, highlighting different hair fibers, foundations, various types of prosthesis, and the most common methods of attachments used to make wigs. Methods: The terms "wigs", "hair" AND "camouflage", "alopecia" AND "camouflage", and "hair prosthesis" were used to perform a literature search in MEDLINE through PubMed until April 8th, 2020. The search was limited to English-language peer-reviewed journal articles about humans, and it included only nonsurgical alternatives to camouflage alopecia. Conclusions: This article will help physicians, especially those who care for patients with hair loss, to provide appropriate advice for their patients about the wide variety and peculiarities of wigs and hairpieces currently available.

No abstract